Skip to content

Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma

Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma: An Immunohistochemical Study.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05550766
Enrollment
50
Registered
2022-09-22
Start date
2022-12-31
Completion date
2023-12-31
Last updated
2022-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-melanoma Skin Cancer

Brief summary

Vitamin D has a crucial role in cancer control and prevention.vitamin D receptor (VDR) and its heterodimer Retinoid X receptor (RXR) are equally important in the cell. This ligand (vitamin D) and receptors (VDR-RXR) complex together triggers downstream DNA damage response in the cell. Retinoid receptors are a superfamily of nuclear receptors. The preferred receptor that attaches to VDR is RXR, with its subunits α, β and γ. RXR α is more frequent in the skin than other tissues, while β occurs in internal organs and γ is frequently related to neural disorders. the investigator hopes to assess prognosis of SCC & BCC by using RXR-α biomarker & attempts to use it in the treatment.

Interventions

None listed

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

1. Squamous cell carcinoma and basal cell carcinoma. 2. Incisional & excisional biopsies. 3. All the studied cases include sufficient materials for the immunohistochemical study 4. Complete clinical data

Exclusion criteria

1. Patients with a history of preoperative chemotherapy and/or radiotherapy. 2. Insufficient or tiny tissue biopsies.

Design outcomes

Primary

MeasureTime frameDescription
Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell CarcinomaOne or two days after staining sections with the marker.immuohistochemical expression of RXR-α in Squamous and Basal Cell Carcinoma

Contacts

Primary ContactFatma M.Hamdan
fatma.mohammad@med.sohag.edu.eg01000419587

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026